Avidity Biosciences Inc (RNA) is predicted to post EPS of -0.80 in the upcoming quarter : This Stock is Ticking Every Box for Top Investors

As on Thursday, Avidity Biosciences Inc (NASDAQ: RNA) started slowly as it slid -5.02% to $23.83, before settling in for the price of $25.09 at the close. Taking a more long-term approach, RNA posted a 52-week range of $4.82-$27.66.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 148.90%. Meanwhile, its Annual Earning per share during the time was -57.60%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -10.57%. This publicly-traded company’s shares outstanding now amounts to $79.28 million, simultaneously with a float of $71.37 million. The organization now has a market capitalization sitting at $1.90 billion. At the time of writing, stock’s 50-day Moving Average stood at $21.69, while the 200-day Moving Average is $11.61.

Avidity Biosciences Inc (RNA) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Avidity Biosciences Inc’s current insider ownership accounts for 10.48%, in contrast to 98.65% institutional ownership. According to the most recent insider trade that took place on Apr 19 ’24, this organization’s Director sold 5,000 shares at the rate of 22.82, making the entire transaction reach 114,123 in total value, affecting insider ownership by 14,830. Preceding that transaction, on Apr 03 ’24, Company’s Director sold 20,000 for 27.11, making the whole transaction’s value amount to 542,214. This particular insider is now the holder of 253,872 in total.

Avidity Biosciences Inc (RNA) Earnings and Revenue Records

Avidity Biosciences Inc’s EPS decrease for this current 12-month fiscal period is -10.57% and is forecasted to reach -3.49 in the upcoming year.

Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators

Let’s observe the current performance indicators for Avidity Biosciences Inc (RNA). It’s Quick Ratio in the last reported quarter now stands at 7.58. The Stock has managed to achieve an average true range (ATR) of 1.53. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 198.72.

In the same vein, RNA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.90, a figure that is expected to reach -0.80 in the next quarter, and analysts are predicting that it will be -3.49 at the market close of one year from today.

Technical Analysis of Avidity Biosciences Inc (RNA)

Through scrutinizing the latest numbers posted by the [Avidity Biosciences Inc, RNA], it can be observed that its last 5-days Average volume of 0.92 million was lower the volume of 1.17 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 64.73% While, its Average True Range was 1.52.

Raw Stochastic average of Avidity Biosciences Inc (RNA) in the period of the previous 100 days is set at 81.65%, which indicates a major rise in contrast to 42.06% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 49.26% that was lower than 77.00% volatility it exhibited in the past 100-days period.